T 1592/12 (Herceptin dosage regimen/GENENTECH) of 25.10.2016
- European Case Law Identifier
- ECLI:EP:BA:2016:T159212.20161025
- Date of decision
- 25 October 2016
- Case number
- T 1592/12
- Petition for review of
- -
- Application number
- 00959423.5
- IPC class
- C07K 16/32A61K 39/395
- Language of proceedings
- English
- Distribution
- No distribution (D)
- Download
- Decision in English
- OJ versions
- No OJ links found
- Other decisions for this case
- -
- Abstracts for this decision
- -
- Application title
- Dosages for treatment with anti-ErbB2 antibodies
- Applicant name
- Genentech, Inc.
- Opponent name
- BioGeneriX AG
Stada R & D GmbH
Teva Pharmaceutical Industries Ltd.
Celltrion, Inc.
Sandoz AG
Synthon B.V. - Board
- 3.3.04
- Headnote
- -
- Relevant legal provisions
- European Patent Convention Art 114(2)European Patent Convention Art 83Rules of procedure of the Boards of Appeal Art 13(1)Rules of procedure of the Boards of Appeal Art 13(3)
- Keywords
- Sufficiency of disclosure - main (sole) request (no)
- Catchword
- -
Order
For these reasons it is decided that:
The appeal is dismissed.